Dr. Jack Kolenda from Toronto and Lux Vitae Worldwide Announce That The Steriwave Nasal Decolonization Treatment Has Been Successfully Used By The Rock Band KISS Since September of 2021, To Prevent The Transmission And Spread of Covid 19
Dr. Jack Kolenda from Toronto and Lux Vitae Worldwide Are Pleased To Announce That The Steriwave Nasal Decolonization Treatment, Has Been Successfully Used By The Rock Band KISS Since September of 2021, To Prevent The Transmission And Spread of Covid 19 on Their World Tour and In Treatment of Covid 19 Positive Individuals In Toronto and Throughout Canada.
Doc McGhee, the legendary manager of KISS says, "It would be impossible, not improbable, but impossible, for KISS to continue on its world tour without the protection of the Steriwave treatment."
MONDAY, MARCH 6, 2023 10 AM, TORONTO, ONTARIO, CANADA
Location: Vantage Venues, Conference Room S1, The Sun Life Tower, 150 King Street West, 27th Floor, Toronto ( when you arrive at the 27th Floor, please see reception and advise them that you are attending the Lux Vitae press conference)
For Press Conference Details and to confirm attendance please call:
HOSTED BY ROD BLACK
DR. JACK KOLENDA, ENT SURGEON AND MEDICAL DIRECTOR OF VERSO SURGERY, OAKVILLE, ONTARIO, CANADA
DOC MCGHEE, THE MANAGER OF KISS
MICHAEL "PINBALL" CLEMONS
GARY LEEMAN, FORMER TORONTO MAPLE LEAFS PLAYER, MONTREAL CANADIENS PLAYER AND STANLEY CUP WINNER
DR. JOSEP ARGEMI, MD, PhD, INTERNAL MEDICINE DEPARTMENT, THE UNIVERSITY OF NAVARRA IN PAMPLONA, SPAIN
GARY SEGAL, PAST CHAIR OF THE VANCOUVER GENERAL HOSPITAL UBC FOUNDATION
At a time when many sports teams and entertainers were isolating themselves due to the threat of COVID-19, in August of 2021 the rock band, KISS, embarked on the largest rock and roll music tour since the beginning of the Coronavirus pandemic with a planned tour through 61 cities in 31 countries on four continents of the world. On their date in Philadelphia on August 26, 2021 Paul Stanley the co founder, lead vocalist and lead guitarist of KISS contracted the Covid 19 infection and KISS had to cancel 9 concert dates at the beginning of their world tour. The legendary manager of KISS, Doc McGhee, had heard about the Steriwave nasal decolonization treatment and after substantial due diligence, made the decision to deploy the Steriwave treatment on the KISS world tour.
Under the oversight of Dr. Jack Kolenda, an ENT surgeon and the medical director of the Verso Surgery Centre in Oakville, Ontario, Canada, and Lux Vitae Worldwide, Doc McGhee, manager of KISS, deployed the Steriwave nasal decolonization treatment to protect the KISS band, management and crew during its world tour, to prevent the transmission and spread of Covid 19. The treatment protocol required KISS and its management and crew to treat themselves with the Steriwave treatment for four minutes every show day, which is the exact same treatment protocol that has been used at Vancouver General Hospital, as the standard of care for more than 12 years, to treat almost all patients prior to surgery, to protect against the spread of MRSA and other hospital acquired infections.
The Steriwave COVID-19 protocol, perfected during the pandemic by Dr. Jack Kolenda, was used to treat 344 patients Covid 19 positive individuals with the Steriwave treatment, to reduce the systemic progression of symptoms of Covid 19 and to promote more rapid healing. Several of these patients, will be present at the press conference to report on their personal experiences with the Steriwave treatment.
Dr. Kolenda had been utilizing the Steriwave nasal decolonization treatment for the same purpose it has been used for at Vancouver General Hospital, to prevent his patients from contracting surgical site infections after surgery. At the onset of the Covid 19 pandemic, in the absence of any preventive measures for the prevention of transmission and spread of Covid 19 and the absence of any treatments for Covid 19 positive individuals, Dr. Kolenda reviewed existing literature and observed that patients with lower viral and bacterial loads in the nose were less likely to die or be hospitalized. With this information, Dr. Kolenda initiated the use of the Steriwave for treatment for his staff and patients to prevent the transmission and spread of Covid 19. The adoption of the Steriwave treatment in his surgery centre had a protective effect against Covid 19 infections among his staff, thereby encouraging Dr. Kolenda to expand the use of the Steriwave treatment to create a treatment protocol, The Kolenda Argemi protocol, which informed successful clinical trials at Sunnybrook Hospital (Toronto) and the Clinica University of Navarra, a world leading medical and research institute in Pamplona, Spain. Both of these trials subsequently demonstrated substantial reduction of viral load in the anterior nares (the front of the nose) and reduction of Covid 19 infectivity in Covid 19 positive patients.
The Steriwave nasal photodisinfection treatment is a non-antibiotic, light-based, antimicrobial therapy developed by Vancouver based Ondine Biomedical. Steriwave is able to quickly eradicate all variants of the Coronavirus and any infective bacterial or fungal co-factors in minutes. The Steriwave Covid 19 treatment protocol developed by Dr. Kolenda and Dr. Josep Maria Argemi, is a topical noninvasive, antiviral, upper respiratory tract treatment, that kills the coronavirus in the anterior nares, a primary source of infection. In 2021, the Steriwave treatment received international recognition by the International Conference of Prevention and Infection Control (ICPIC), Geneva as an Innovation Excellence Award winner for the use of the Steriwave treatment, in the treatment of Covid 19 positive individuals.
Dr. Kolenda was the first doctor in the world to provide the Steriwave treatment to Covid 19 positive patients, some of whom were immunocompromised, and highly symptomatic, observing rapid resolution of Covid 19 symptoms in all of the individuals treated with the Steriwave treatment. Highly importantly, none of the Covid 19 positive patients treated with the Steriwave treatment were admitted to hospital. There was recent confirmation of the efficacy of the Steriwave, Kolenda Argemi treatment protocol in a randomized control trial study of COVID-19 patients which was carried out by the Clinica Universidad de Navarra in Pamplona, Spain and published in Frontiers in Cellular and Infection Microbiology (https://www.frontiersin.org/articles/10.3389/fcimb.2023.1110467/full). The University of Navarra randomized control trial demonstrated that the Steriwave treatment was able to substantially reduce viral load in the anterior nares (front of the nose), substantially reducing Covid 19 infectivity as well as rapidly resolving COVID symptoms.
Lead author, co-principal investigator, and Associate Professor at the Department of Occupational Medicine at the University of Navarra, Dr Alejandro Fernandez-Montero commented, "This randomized, controlled study shows that photodisinfection could be an effective and safe novel treatment for SARS-CoV-2 carriers, significantly decreasing the infectivity period. Most exciting is the demonstration of an adaptive immune response in treated patients. This is the basis of vaccination, and it means that nasal decolonization might provide an alternative, low-cost, widely accessible, respiratory virus treatment during future pandemics. The treatment specifically helped to maintain, over time, the cell-mediated immunity, which is remarkable as this is the immune protection needed against severe disease."
Dr. José Luis Del Pozo, Head of Infectious Diseases Division and Clinical Microbiology at the Clínica Universidad de Navarra, Co-Principal Investigator, and Study Author, commented "This study expanded our understanding of SARS-CoV-2 pathogenesis, because interestingly, we showed that treatment with aPDT applied only to the nasal passages also reduced SARS-CoV-2 colonization of the nasopharyngeal region. This implies that we might be able to slow viral spread from the upper to the lower respiratory tract, reducing the extent of illness and thereby reducing pressure on hospital facilities such as the ICU. It also means that we might be able to slow or inhibit viral spread from person to person during an outbreak, in both clinical and non-clinical settings, even when those patients have been previously vaccinated."
A significant finding of the randomized control trial is that Steriwave photodisinfection substantially prolonged patient immunity against Covid 19 at 20 weeks after treatment. This finding suggests that the Steriwave treatment is one of the most important innovations in the fight against coronaviruses and other respiratory pathogens. The Steriwave treatment has been proven to be safe and effective for both prevention of the transmission and spread of Covid 19 and treatment of COVID-19 positive patients and is a highly effective solution to protect front line workers and health professionals as part of PPE.
In a recent press release commenting on the University of Navarra, Steriwave randomized control trial results, Ondine Biomedical founder and CEO, Carolyn Cross, stated " The Clínica Universidad de Navarra study sheds new light on the Steriwave treatment of respiratory viruses, where antibiotics are entirely ineffective and new anti-viral therapies are limited. As new Covid 19 variants rapidly emerge across the globe, we look forward to being able to play our part in helping our communities, hospitals, clinics, and emergency workers deal with these new threats. Steriwave has been successfully used in Canadian hospital surgical suites for more than ten years, significantly reducing post-surgical infection rates, length of stay and hospital readmission rates. Eliminating a broad spectrum of pathogens from the nose prior to surgery has proven to be a major factor in reducing hospital-acquired infections in these hospitals. More than 100,000 patients have already benefited from this painless, rapid approach to infection control – all without the fear of resistance formation and the possibility of antibiotic adverse effects."
The Steriwave nasal photodisinfection decolonization treatment was developed and is produced by Ondine Biomedical, a Vancouver-based life sciences company (www.ondinebio.com), which trades on the London AIM Stock Exchange under the trading symbol (OBI). Ondine Biomedical is the world leader in developing and creating antimicrobial photodisinfection treatments and technologies with 7 products in its pipeline.
The Steriwave antimicrobial photodynamic therapy treatment and technology eradicate and mitigate, what the WHO, CDC and the Bill and Melinda Gates Foundation identify as one of the greatest threats to humanity in the next decade; antibiotic resistant infection and antimicrobial resistance (AMR).
The Steriwave treatment is approved in Canada, The European Union, The United Kingdom, Ireland, Australia and Mexico.
The Steriwave treatment is not for sale or distribution in the United States.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230305005049/en/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lenovo ranks Eighth in the Gartner® Supply Chain Top 25 for 202330.5.2023 20:11:00 EEST | Press release
Lenovo has once again been named in the Gartner Supply Chain Top 25 for 2023, ranking eighth in this list of global companies with supply chains. The Gartner Supply Chain Top 25 identifies, celebrates and profiles supply chain excellence on a global scale, and by target region and industry. Now in its 19th year, the global ranking is a peer benchmark for chief supply chain officers (CSCO) and their teams, inspiring innovation and leadership. The Supply Chain Top 25 ranking comprises two main components: business performance and opinion. Business performance in the form of public financial and ESG (environmental, social, governance) data provides a view into how companies have performed in the past three years, while the opinion component offers an eye to future potential and reflects leadership in the supply chain community. These two components are combined into a total composite score. Lenovo has fully embraced digital transformation within its complex and global supply chain, and by
Wemade’s MMORPG MIR M Reveals New Content ‘Monster Dungeon’30.5.2023 16:00:00 EEST | Press release
Wemade's MMORPG MIR M: Vanguard and Vagabond showcased new content, "Monster Dungeon," on May 30th. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230530005249/en/ MIR M reveals new “Monster Invasion” content on May 30. (Graphic: Wemade) Users can obtain the "Demonic Stones" of field monsters they have defeated. Each "Demonic Stone" can be used to summon that monster in Monster Dungeon. By defeating all summoned monsters, users can obtain "Essence" items as rewards. "Essence" items can be registered to the Monster Codex to increase character stats. MIR M will be holding the event "Grand Operation Defeat Giant Scarecrow" until the update on June 13th. Users can defeat the Giant Scarecrow that appears in the Ginkgo Valley area to obtain gifts such as "Giant Scarecrow Raid Chests" and "Giant Scarecrow Demonic Stones." By using "Giant Scarecrow Demonic Stones," users can obtain Demonic Stones that can be used to summon boss mons
Q4 Inc. Set to Transform IR Effectiveness with Generative AI on the Q4 Platform30.5.2023 14:30:00 EEST | Press release
Q4 Inc. (TSX: QFOR) (“Q4” or “the Company”), the leading capital markets access platform, is excited to announce progress on pioneering generative artificial intelligence (“AI”) that is purpose built for Investor Relations (“IR”) effectiveness to help automate common tasks and accelerate decision making. By combining AI with the industry’s only end-to-end IR platform, IROs will be able to find insights exclusive to them built on a pool of their own proprietary program data and capital markets data aggregated on the Q4 Platform. “We are embarking on one of the most exciting product cycles in our history,” remarked Darrell Heaps, Founder and CEO of Q4. “Our offerings will unlock tremendous new opportunities for our clients to benefit from the unmatched richness and scale of our proprietary data with the integration of generative AI. The result for clients will simply be effective investor relations and better insights for our investment banking and equity capital markets clients.” In the
Kinaxis RapidResponse Available on Google Cloud Marketplace30.5.2023 14:00:00 EEST | Press release
Kinaxis ® Inc. (TSX: KXS), the authority in driving agility for fast, confident decision-making in an unpredictable world, announced today announced that the market’s leading supply chain management solution, Kinaxis RapidResponse® is available on Google Cloud and in the Marketplace. RapidResponse supports key business processes such as demand and supply planning, integrated business planning, sales and operations planning (S&OP) and inventory management, and delivers end-to-end transparency with its control tower capabilities. Concurrent planning breaks down organizational silos, unifies disparate data under a single all-inclusive data model, and codifies business-wide trust through the continuous alignment of everyone and everything across a company’s end-to-end supply chain. “We’re pleased the Kinaxis platform is now available on Google Cloud,” said Dai Vu, Managing Director, Cloud Marketplace & ISV GTM Initiatives at Google Cloud. “Customers can deploy Kinaxis via the Google Cloud
New Clinical Data on Vuse Illustrates Beneficial Public Health Impact of Tobacco Harm Reduction30.5.2023 13:00:00 EEST | Press release
New results from one of the largest ever vapour product studies, which analysed BAT’s flagship vapour brand Vuse, have been published in the journal of Internal and Emergency Medicine (https://link.springer.com/article/10.1007/s11739-023-03294-9). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230530005321/en/ One of the largest ever vapour product studies compared clinical measurements from exclusive Vuse consumers with smokers (Graphic: Business Wire) The study compared clinical measurements from exclusive Vuse consumers with smokers. The results of the study show that participating Vuse consumers had favourable differences in biomarkers of exposure (BoE) and biomarkers of potential harm (BoPH) relevant to smoking-related diseases when compared to smokers. Vuse users have shown significantly lower biomarkers of exposure for priority cigarette smoke toxicants as defined by the World Health Organization (WHO)iii. The data al
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom